Figure 7
ALCAM-Iso2 expression correlates with disease progression. (a) Representative images of in vitro cell aggregation analysis of parental UMUC-3 cells (U_Par) and UMUC-3 ALCAM knockout cells (U_KO) transiently expressing ALCAM-Iso1 (U_KO + Iso1) or ALCAM-Iso2 (U_KO + Iso2). Veh, vehicle (0.4% DMSO), A-Fc, soluble ALCAM-Fc (10 μg/mL), MPi, metalloprotease inhibitor (GM6001, 10 μM). (b) Quantification of in vitro cell aggregation assay. Clusters were binned into single cell, small (Sm), medium (Med), large (Lrg), or extra-large (XL) clusters based on pixel area. Distribution of clusters across size bins was represented as percent of total area of all clusters. P-values were calculated using Chi-square test for trend and are listed in Supplementary Table ST6. Results are representative of three independent experiments. (c) Expression of ALCAM-Iso1 and ALCAM-Iso2 in normal bladder and bladder cancer. Data for normal bladder tissue were extracted from the GTEx Portal. Data for bladder cancer tissue were extracted from the TCGA bladder cancer cohort. p-values were calculated using paired t-test, ****p < 0.0001. Graphs display mean with 95% confidence interval. Medians are reported. (d) Relative abundance of ALCAM-Iso2 in normal and bladder cancer tissue. P-value calculated with Mann-Whitney U test. Graphs display mean with 95% confidence interval. Medians are reported.
